700 liver transplant patients studied to uncover hidden clot risks

NCT ID NCT06513780

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study follows 700 adult liver transplant recipients to understand how portal vein thrombosis (a blood clot in the liver's main vein) impacts their recovery and long-term health. Researchers will compare those with and without the clot to identify risk factors and build a prediction tool. No treatment or intervention is given—this is purely to gather knowledge.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors better predict and manage complications like portal vein thrombosis after liver transplant, improving patient care.

What could go wrong

This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all transplant patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PORTAL VEIN THROMBOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

portal vein thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Friendship Hospital, Capital Medical University

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••